CAR T-Cell Therapy: Applying the Data, Tailoring Treatment, and Future Considerations

CAR T-Cell Therapy: Applying the Data, Tailoring Treatment, and Future Considerations

Friday, June 26, 2020
Webinar -- 12:00 PM ET
https://www.clinicaloptions.com/CARTWebinarSummer2020Join2

Agenda

  • Welcome and Introduction
  • Overview of CAR T-Cell Therapy (Michael R. Bishop, MD)
  • Review of Clinical Outcomes of CAR T-Cell Therapies for ALL (Daniel J. DeAngelo, MD, PhD)
  • CAR T-Cell Therapy Against NHL and CLL: Current and Emerging Clinical Trial Evidence (Michael R. Bishop, MD)
  • The Future of CAR T-Cell Therapy for Myeloma (Noopur Raje, MD)
  • Identifying and Managing CAR T-Cell–Mediated Toxicities (Noopur Raje, MD)
  • Final Thoughts and Audience Question and Answer Session

Faculty

Program Director
Michael R. Bishop, MD

Professor of Medicine
Director
, Hematopoietic Stem Cell Transplantation Program
University of Chicago
Chicago, Illinois

Faculty
Daniel DeAngelo, MD

Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Faculty
Noopur Raje, MD

Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Goal Statement
The goal of this activity is to improve the knowledge of physicians and other healthcare providers of CAR T-cell therapies so they can confidently and competently integrate these treatments into their clinical practices.

Target Audience
This program is intended for physicians and other healthcare providers who treat and manage patients with leukemia, lymphoma, or myeloma who are candidates for CAR T-cell therapies.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Review the biologic principles underlying CAR T-cell therapy, structure and function of the CAR, and the mechanism of action of CAR T-cells
  • Identify characteristics of patients that are appropriate for treatment with CAR T-cell therapy
  • Review the clinical trial data on CAR T-cell–based therapies for the treatment of patients with leukemia and lymphoma, and describe where CAR T-cell therapies might fit into the treatment landscape
  • Evaluate emerging clinical data and novel approaches to CAR T-cell therapy for patients with myeloma
  • Based on the current best evidence, implement strategies for managing toxicities associated with CAR T-cell therapy
  • Recall ongoing clinical trials evaluating CAR T-cell therapy for the treatment of leukemia, lymphoma, and myeloma to aid in the referral of appropriate patients

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification
Successful completion of this activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.